This proposal explores the relationship between the levels of free functional eIF-4E (the mRNA cap binding protein) and the tumorigenic and metastatic properties of human breast cancer cell lines. Previous studies have shown that eIF-4E is elevated in human breast carcinomas as well as in established breast carcinoma cell lines when compared to normal or benign disease controls. EIF-4E is considered the rate limiting factor in the formation of the eIF-4E initiation complex, the rate-limiting factor in the translation of messenger RNAs. Increased eIF-4E levels have profound influences on the efficiency of translation of certain mRNAs which have long 5'-untranslated leader sequences, high GC content, and upstream in-frame initiation condons. This mRNA group includes many oncogenes (transcription and growth factors) as well as potent angiogenesis factors such as bFGF and VEFG. EIF-4E is also regulated by a binding protein (4EBP-PHAS-1) which can form complexes with eIF-r# in a non-phosphorylated state. This proposal examines the effects of reducing eIF-4E, increasing PHAS-1, or modifying the activities of complexes and the resultant effect on the level of eIF-4E which can participate in mRNA translation. The effect of these interactions on the expression of translationally regulated bFGF and VEGF are studied in comparison to non-translationally regulated B-actin and ras. Additionally, the effect of these interactions on the initiation and growth of breast cancer tumors will be investigated. Tissue samples from established tumors will be examined for the interaction between eIF-4E and 4EBP/PHAS-1 and resultant effect on expression of translationally and nontranslationally regulated molecules. These samples will be taken to monitor the effects of the treatment of the tumors with genes or drugs that affect eIF-4E function.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA077614-03
Application #
6342082
Study Section
Pathology B Study Section (PTHB)
Program Officer
Gallahan, Daniel L
Project Start
1999-01-01
Project End
2002-12-31
Budget Start
2001-01-01
Budget End
2001-12-31
Support Year
3
Fiscal Year
2001
Total Cost
$178,383
Indirect Cost
Name
University of Kentucky
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506
Greenberg, Victoria L; Zimmer, Stephen G (2005) Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene 24:4851-60
Bevins, Robert L; Zimmer, Stephen G (2005) It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 65:6957-66
Chobanian, Nishan H; Greenberg, Victoria L; Gass, Jennifer M et al. (2004) Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res 24:539-45
Graff, Jeremy R; Zimmer, Stephen G (2003) Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20:265-73
Shenberger, Jeffrey S; Adams, Mary H; Zimmer, Stephen G (2002) Oxidant-induced hypertrophy of A549 cells is accompanied by alterations in eukaryotic translation initiation factor 4E and 4E-binding protein-1. Am J Respir Cell Mol Biol 27:250-6
Greenberg, V L; Williams, J M; Cogswell, J P et al. (2001) Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11:315-25
Greenberg, V L; Williams, J M; Boghaert, E et al. (2001) Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. Thyroid 11:21-9
Zimmer, S G; DeBenedetti, A; Graff, J R (2000) Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20:1343-51